Skip to main content
    B

    Beta Bionics, Inc. Common Stock (BBNX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $15.21
    -1.21 (-7.37%)

    Market Cap: $892.71M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Beta Bionics, Inc. Common Stock (BBNX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Beta Bionics, Inc. Common Stock (BBNX) to earn -$1.83 per share in the fiscal year ending Dec 31, 2026, on revenue of $125.54M. Of 15 analysts, 11 rate the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 2.13, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 73% of the ratings.

    RatingAnalystsShare
    Strong Buy213.3%
    Buy960.0%
    Hold426.7%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    15

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 47.1%.

    Fiscal year ending Dec 31, 2026
    -$1.83
    EPS consensus, revenue $125.54M
    Fiscal year ending Dec 31, 2027
    -$2.18
    EPS consensus, revenue $184.65M
    Next report
    Feb 15, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$1.83-$2.00 to -$1.513$125.54M$123.93M to $127.40M14
    Dec 31, 2027-$2.18-$2.76 to -$1.853$184.65M$170.88M to $194.00M14

    Quarterly Estimates

    The EPS consensus falls from -$0.51 for the quarter ending Dec 31, 2026 to -$0.53 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.51-$0.62 to -$0.4516$31.03M$28.21M to $33.91M16
    Mar 31, 2027-$0.53-$0.62 to -$0.432$35.34M$33.20M to $38.10M10

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 4 upward and 2 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202620
    Fiscal year ending Dec 31, 202711
    Quarter ending Mar 31, 202711

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$2.06.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$1.83-$1.88-$1.84-$1.90-$2.06N/A
    Fiscal year ending Dec 31, 2027-$2.18-$2.16-$2.33-$2.32-$2.34N/A
    Quarter ending Mar 31, 2027-$0.53-$0.53-$0.53-$0.56-$0.57N/A

    Frequently Asked Questions About BBNX

    What is the BBNX stock forecast?

    Consensus analyst estimates put Beta Bionics, Inc. Common Stock's EPS at -$1.83 for the fiscal year ending Dec 31, 2026, on revenue of $125.54M. The consensus rating from 15 analysts is Buy.

    How do analysts rate BBNX stock?

    Of 15 analysts covering Beta Bionics, Inc. Common Stock, 2 rate it Strong Buy, 9 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from BBNX next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.83, with estimates from -$2.00 to -$1.51 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.18, with estimates from -$2.76 to -$1.85 from 3 analysts.

    What revenue do analysts expect from Beta Bionics, Inc. Common Stock next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $125.54M, with estimates from $123.93M to $127.40M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $184.65M, with estimates from $170.88M to $194.00M.

    How many analysts cover BBNX?

    15 analysts rate Beta Bionics, Inc. Common Stock stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.